• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
three spotlights on a stage
Biotech

Bhattacharya faces Senate grilling on NIH disruptions

“In total, the NIH has terminated or frozen at least $561 million in research and defunded more than 300 clinical trials ...,” Bernie Sanders said.
Gabrielle Masson Feb 3, 2026 5:20pm
vaccine sales

HHS launches $100M prize to develop antiviral therapies

Feb 3, 2026 4:00pm
Inside Henlius global growth strategy
Sponsored

Inside Henlius’ global growth strategy

Feb 2, 2026 8:00am
Charles River Boston Massachusetts

Charles River to close Maryland CDMO site, lay off 20 staffers

Feb 3, 2026 12:20pm
Vinay Prasad

FDA to ‘carefully shepherd’ CAR-T for autoimmune disease: Prasad

Feb 3, 2026 11:40am
drawing of magnifying glass on a brain

Exxel plans $13M IPO to score where other FAAH inhibitors failed

Feb 3, 2026 11:33am
More News

Bourla says pipeline pruning is mostly done after 6 more culls

Feb 3, 2026 11:33am

Pfizer links monthly GLP-1 to competitive weight loss in phase 2

Feb 3, 2026 8:45am

NMD accelerates rare disease asset despite primary endpoint miss

Feb 3, 2026 4:30am

Novo’s CagriSema tops semaglutide in ph. 3 diabetes study

Feb 2, 2026 3:01pm
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings